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Chapter 1
Introduction: The human immune system
1.1 Discovery
The first description of the existence of the human immune system roots in the accurate docu-
mentation of the plague in Athens during the Peloponnesian War by the ancient Greek historian
Thukydides. Beside his notable description of signs and symptoms of this particular disease he
emphasized that only previously infected and cured persons were protected and could care for
the ill citizens (Littman, 2009). Here, by describing immunological memory, Thukydides states
one of the four known key features of the body’s adaptive immune system (specificity, diversity,
recognition of self and nonself, memory), which puts him far ahead of his time. Although fur-
ther knowledge was gathered over time, the next milestone of immunology was not set until the
late 18th century, when Edward Jenner discovered the protective effect of cow pox against small
pox infection and thereby invented the first vaccine in history (Smith, 2011). Another hundred
years later, Elie Metchnikoff discovered that white blood cells cover and engulf foreign bodies in
starfish larvae and proposed that this mechanism (phagocytosis) might be responsible for the elim-
ination of bacteria by leukocytes too (Tauber, 2003). Roughly at the same time, Emil Behring
and Kitasato Shibasaburo developed the first antitoxin, an antibody against the diphtheria toxin
by inoculating horses with the purified toxin. Thus, Behring and Kitasato unintentionally found
the first evidence of the existence of the adaptive humoral immunity (Behring and Kitasato, 1890).
During the 20th century, the field of immunological research widely expanded and several highly
important discoveries were made all around the world, e.g. the existence of major histocompati-
bility complexes (MHC) (Snell and Higgins, 1951), the structure of immunoglobulins (Edelman
and Gally, 1962), the existence and development of T and B cells (Miller and Mitchell, 1968), the
antigen-presentation capacity of dendritic cells (Steinman and Witmer, 1978) and the regulatory
potential of certain subsets of immune cells (Sakaguchi et al., 1995).
The current knowledge on the human immune system has allowed us to translate it into clinics
not only in terms of prophylactic vaccination and therapeutic immunosuppression but also in treat-
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ment of malignancies. For instance, the great improvements in treatment of malignant melanoma
and other malignancies by using the so called checkpoint inhibitors (e.g. ipilimumab or nivolumab)
show the tremendous potential of therapeutical immunomodulation.
The human immune system is composed by the innate and the adaptive immune system. The
innate defense mechanisms act immediately and unspecificly upon activation whereas the delayed
adaptive response is highly specific and can generate a long-lasting immunologic memory. Al-
though this separation is somehow arbitrary and does not represent the complexity of the immune
system, this systematic approach shall be followed due to its simplicity and lucidity.
1.2 The innate immune system
1.2.1 Cell types
The innate immune system is phylogenetically older than the adaptive one and can be found in
almost every higher organism, e.g. plants, fungi, invertebrates and vertebrates (Schulenburg et al.,
2004). It consists of several cell types, which are largely mature and functional at time of birth
(Table 1.1).
Table 1.1: Innate immune cells
Cell type Main function Main localization
Neutrophils Anti-bacterial activity Circulating
Eosinophils Anti-parasitic activity Circulating
Basophils Production of cytokines and mediators Circulating
Mast cells Production of cytokines and mediators Tissue-resident
Monocytes Precursor cells of macrophages Circulating
Macrophages Phagocytosis of bacteria and debris Tissue-resident
Natural killer cells Anti-viral and anti-tumor activity Circulating
Dendritic cells Antigen presentation Tissue-resident
Epithelial cells Barrier function Tissue-resident
Neutrophilic granulocytes represent the biggest fraction of leukocytes in the human blood and
show a distinct morphology when observed in the peripheral blood smear: According to their mat-
uration status they contain a rod- or barlike nucleus (less mature), a 3- to 5-fold segmented nucleus
(mature) or more than 5-fold hypersegmented nucleus (aged) and largely neutral stained cytoplas-
mic granules in routinely stained blood smears. Neutrophils combat bacterial infections mainly by
phagocytosis and degranulation upon activation releasing antimicrobial enzymes and proteins, e.g.
defensins, lactoferrin and lysozyme.
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Eosinophils are hardly found in peripheral blood smears , since they account for less than 5%
of circulating leucocytes, whereas they compose 20-30% of the intestinal lamina propria-resident
cells (Jung and Rothenberg, 2014). Their eosinophilic cytoplasmic granula containing cytotoxic
cationic proteins (e.g. major basic protein and eosinophil peroxidase) are the name-giving key
property of this particular cell type. Eosinophils are involved in anti-helminthic responses and
are commonly associated with hypersensitivity disorders like asthma and eosinophilic esophagitis
(Rothenberg and Hogan, 2006).
Basophils and mast cells are often grouped together due to their highly similar morphology and
function. Both possess many (basophilic) granules containing histamine, heparin and various
eicosanoids and cytokines. They are considered as regulators of innate and adaptive immunity,
might contribute to anti-parasitic defense and seem to have a crucial role in inducing a type 2
immune response (see below) (Voehringer, 2013). Furthermore, basophils and mast cells are key
effector cells in pathologic conditions such as anaphylaxia and allergic asthma.
Macrophages and their circulating precursor cells (monocytes) are the main phagocytes in the
human body. Macrophages are found in essentially every tissue and have - at least in part - tissue
specific differentiation represented by tissue specific names, e.g. Kupffer cells, Hofbauer cells or
osteoclasts. They ingest not only bacteria, but any foreign bodies, cancer cells and cellular debris,
that is detected as non-self or non-intact by their pattern recognition receptors (PRRs). Although
the common classification of macrophages in M1 and M2 subtypes has been discussed contro-
versially in literature due to its great simplification and subsumption, it shall be followed in the
following (Varol et al., 2015): M1 macrophages are considered to be the ”killer” macrophages with
pro-inflammatory properties such as secretion of high levels of IL-12, whereas M2 macrophages
are believed to be designated to repairing and wound healing due to their immunosuppressive func-
tions, e.g. secretion IL-10 and TGF-. Interestingly, some tissue-specific macrophages, e.g. cere-
bral macrophages, the so-called microglia, seem to develop independently from the bone marrow
hematopoietic stem cells but originate from yolk sac hematopoietic stem cells and persist through-
out life (Schulz et al., 2012).
Natural killer (NK) cells are subsumed among the group of innate immune cells, which originate
mostly from the myeloid lineage, although they differentiate from the lymphoid hematopoietic
stem cell. In contrast to other immune cells, NK cells do not rely on MHC proteins or antibodies
in order to detect infected or dedifferentiated cells due to their unique subsets of activating (e.g.
NKG2D) and inhibitory receptors (e.g. CD94/NKG2A heterodimers). This allows a much faster
response in case of infection, since no previous immunization is needed (Vivier et al., 2011).
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Dendritic cells (DCs) were discovered in 1973, although the skin-homing subpopulation of DCs,
the so-called Langerhans cells, were identified more than 100 years earlier (Steinman and Cohn,
1973). They play a pivotal role in translating an innate into an adaptive immune response by periph-
eral ingestion of microbes or tumor cells, migration to secondary lymphoid organs and presenta-
tion of processed antigens on MHC proteins to T and B cells. Several subtypes of DCs have been
described in literature according to specific surface markers and functions, such as plasmacytoid
dendritic cells (pDCs) and classical DCs (cDCs) (Merad et al., 2013). Recently, the therapeutic
exploitation of the antigen-presentation capacity of DCs has been subject of intensive investiga-
tion, since DC-based anti-tumor vaccines seem to be a promising approach in order to enhance
the anti-tumor immune response (Radford et al., 2014).
Additionally, epithelial cells are considered as innate immune cells by some authors due to their
barrier-function, which helps to repell invading pathogens, and their secretory capacity of an-
timicrobial proteins such as defensins and lysozyme. Furthermore, endothelial cells mediate di-
apedesis of leucocytes through the endothelial layer by secretion of cytokines and chemokines (e.g.
CXCL8) and the presentation of adhesion-molecules on their surface at the site of inflammation
(Kolaczkowska and Kubes, 2013).
1.2.2 Cytokines and complement factors
The innate immune system is not only composed by immune cells but also by soluble factors as
cytokines and complement factors. Various soluble molecules are subsumed among the term ”cy-
tokines”, which are involved in cell differentiation, activation and communication. Important cy-
tokines are listed below (Table 1.2).
Complement factors are plasma proteins produced in the liver that are crucial for anti-bacterial
defense and seem to play a role in many auto-immune diseases. Complement factors are able to
induce direct lysis of bacteria by forming a so-called membrane-attack complex or by opsonization
of pathogens allowing a better and faster clearance by immune cells.
Additionally, the innate immune system provides directly anti-microbial acting proteins and en-
zymes, e.g. defensins and lysozyme. Defensins are secreted proteins that are capable of immediate
lysis of bacteria, fungi and some kind of viruses by disrupting the microbial membrane integrity
leading to efflux of ions and nutrients. Lysozyme acts by catalyzing the hydrolysis of glycosidic
bonds in specific peptidoglycans forming the bacterial cell wall and is found in many secretions of
the human body.
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Table 1.2: Important cytokines
Cytokines Main function Main producing cell type
IL-1 Activation of immune cells Macrophages, neutrophils
and epithelial cells
IL-1 Activation of immune cells Macrophages and
neutrophils
IL-2 Proliferation of activated T cells Activated T cells
IL-3 Differentiation and proliferation of
hematopoietic progenitor cells
Activated T cells
IL-4 Differentiation of Th0 cells into Th2
cells
Activated T cells
IL-6 Activation of immune cells and
induction of systemic inflammation
Macrophages and
activated T cells
IL-10 Suppression of immune cells Monocytes and regulatory
T cells
IL-12 Differentiation of Th0 cells into Th1
cells
Dendritic cells and
macrophages
IFN- Induction of an anti-viral response Lymphocytes, pDC and
other immune cells
IFN- Activation of immune cells NK cells, activated Th1
and CD8+ T cells
TNF- Activation of immune cells and
induction of systemic inflammation
Activated macrophages
and other immune cells
TGF- Suppression of immune cells Regulatory T cells and
other immune cells
1.2.3 Toll-like receptors
Toll-like receptors (TLRs) are rather non-specific pattern recognition receptors (PRPs), which are
mainly expressed by macrophages, dendritic cells and natural killer cells. These receptors are capa-
ble of recognizing pathogen-associated molecular patterns (PAMPs), which are highly conserved
among microbes such as bacteria, fungi, parasites and viruses. Thereby, TLRs represent an innate
group of first line defense receptors, which are highly important for the initiation and successful
execution of an immune response.
There are eleven TLR-genes in the human genome (TLR1-11), although only ten of them are
actually expressed, since TLR11 is a so-called pseudogene which is not fully transcribed due to
stop codons within the protein coding sequence (Roach et al., 2005). These receptors differ in their
respective binding capability of PAMPs, their subcellular localization and their downstream sig-
naling cascade (Table 1.3, adapted and modified from (Takeda et al., 2003; Beutler, 2009; O’Neill
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et al., 2013)). TLR10 is the only known anti-inflammatory TLR, whereas all the others drive a
strong and immediate inflammatory response upon activation.
Table 1.3: The human toll-like receptor family
Name Ligands Localization Signaling Dimerization
TLR1 Bacterial peptido-
glycan and triacyl
lipopeptides
Cell membrane MyD88/IRAK TLR1/TRL2
TLR2 Lipoteichoic acid,
lipomannan,
zymosan and others
Cell membrane MyD88/IRAK TLR2/TLR1,
TLR2/TLR6
TLR3 Double stranded
RNA
Endosomes TRIF/IRF3
TLR4 Lipopolysaccharide,
fibrinogen, nickel
and others
Cell membrane MyD88/IRAK,
TRIF/IRF3
TLR5 Flagellin, profilin Cell membrane MyD88/IRAK
TLR6 Diacyl lipopeptides Cell membrane MyD88/IRAK TLR6/TLR2
TLR7 Single stranded viral
RNA
Endosomes MyD88/IRAK
TLR8 Single stranded viral
RNA, bacterial
RNA
Endosomes MyD88/IRAK
TLR9 CpG oligo-
nucleotides
(unmethylated)
Endosomes MyD88/IRAK
TLR10 Unknown Cell membrane,
intracellular
PI3K/Akt TLR10/TLR2
Although there are other PRRs such as RIG-I-like receptor dsRNA helicase enzymes (RIG-I,
MDA5, LGP2), TLRs are an essential part of the human immune system and many diseases have
been recently associated to these receptors (Casanova et al., 2011). For instance, missense muta-
tions in the TLR4 gene were found to impair the response to inhaled LPS (Arbour et al., 2000)
and may contribute to an increased risk of gram-negative bacterial infections (Agnese et al., 2002),
although this finding is somehow controversial (Jessen et al., 2007). Defects in the downstream
signaling of TLRs are even more devastating, since they share the same signaling cascade for the
most part. Inherited IRAK-4 deficiency leads to greater susceptibility to invasive and noninvasive
pyogenic bacterial infections due to multiple TLR malfunction (Picard et al., 2003).
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Furthermore, the pro-inflammatory properties of TLRs might contribute to tumorigenesis by
maintaining inflammation and TLR-mediated anti-apoptotic effects. Reversely, TLRs have also
been considered as a promising target in tumor immunotherapy and tumor vaccination strategies
over the last years because of their strong immunostimulatory effect. TLRs are known to enhance
antigen-internalization and -presentation on dendritic cells (West et al., 2004), to promote Type-I
interferon release (Kadowaki et al., 2001) and subsequent NK cell activation and to directly inhibit
Treg functioning (Pasare and Medzhitov, 2003). After many years of basic research, Imiquimod
was the first direct TLR agonist approved by the FDA for treatment of condylomata (Arican et al.,
2004) and basal cell carcinoma (Geisse et al., 2004). By now, other TLR agonist have made their
way into clinical trials either for treatment (e.g. MGN1703 (Schmoll et al., 2014)) or as adjuvants
for peptide vaccinations (e.g. resiquimod (Sabado et al., 2015)).
However, despite encouraging preclinical results, many recent trials using TLR agonists for the
treatment of cancer have shown disappointing results either due to tumor-promoting effects or
severe side effects of these drugs (Guha, 2012). Therefore, using synthetic TLR agonists for the
treatment of malignancies is still in its infancy and requires further basic and clinical research to
fully exploit the therapeutic potential of these receptors without facing adverse effects.
1.3 The adaptive immune system
1.3.1 T and B lymphocytes
The adaptive immune system represents a highly complex and elaborate interplay between cells and
soluble factors allowing specific and long-lasting immune responses upon activation by antigens.
Among others, two main cell types constitute the adaptive immune system: T and B cells.
T and B cells originate from the hematopoietic stem cells in the bone marrow but follow distinct
paths of differentiation. Whereas B cells largely remain in the bone marrow for maturation and
selection processes, T progenitor cells leave the bone marrow in an immature state and home in
the thymus, where they are henceforth called thymocytes. Here, in the cortex of the thymus, the
positive selection process of the double positive thymocytes (CD4+/CD8+) takes place. The pos-
itive selection ensures that only thymocytes capable of binding MHC survive. Interestingly, their
affinity to the two classes of MHC determine the cell’s fate: thymocytes with a high affinity to
MHC might get activated by MHC itself and therefore undergo apoptosis. Cells binding MHC
Class I lose the CD4 surface protein (CD8 single positive) whereas thymocytes interacting with
MHC Class II loose their CD8 protein (CD4 single positive). Cells without or with very weak
MHC binding capacity are of no further use and undergo apoptosis (Palmer and Naeher, 2009).
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Positively selected MHC-restricted single positive thymocytes migrate into the medullary stroma
of the thymus and are negatively selected by tissue-resident medullary thymic epithelial cells ex-
pressing the transcription factor AIRE (autoimmune regulator) allowing the presentation of al-
most every self-antigen found in the body. Thymocytes strongly binding the MHC-presented
self-antigens are negatively selected and undergo apoptosis due to their auto-reactive behavior.
This process is essential for the maintenance of the central tolerance. Cells with intermediate
affinity to the presented self-antigens differentiate into regulatory T cells (Treg), which mainly
suppress other T and B cell populations and are responsible for peripheral tolerance (Hsieh et al.,
2012). Cells without any binding to self-antigens survive and leave the thymus in a functional state.
B cell selection takes place in the bone marrow. Immature B cells express IgM as B cell recep-
tors followed by IgD during their maturation process. The selection process is performed in the
IgM single positive state by clonal deletion or receptor-editing: B cells recognizing self-antigens
on the surface of bone marrow-homing cells either rearrange the antigen-binding fragment of their
B cell receptor in order to lose affinity to self-antigens or undergo apoptosis when receptor editing
is not successful (Halverson et al., 2004).
Mature B and T cells circulate in the blood and lymphatic vessels and home to the secondary
lymphatic organs, like tonsils, lymph nodes and spleen. There, they rest in a naive state ready for
antigen recognition and activation. Although the activation processes of B and T cells are com-
pletely different, they share the requirement of two activation signals and are dependent on each
other. Whereas B cells can recognize unprocessed and non-MHC-presented antigens, T cells rely
on antigen-processing and -presentation onMHCClass I and II.When a specific, but naive CD4+
T cell (Th0) finds its antigen presented on MHC Class II of an antigen-presenting dendritic cell
(first signal) and receives a costimulatory signal (second signal) simultaniously, it differentiates into
a antigen-primed and therefore activated helper T cell. Costimulation usually occurs by activation
of CD28 on T cells by CD80/86-binding provided by antigen-presenting cells. Depending on the
cytokine milieu, the CD4+ T cell will either differentiate into a Th1, Th2, Th3, Th9, Th17, Tfh
or Treg and expand clonally by autocrine IL-2 signaling. The characteristics of each helper T cell
subtype are depicted below (Table 1.4).
CD8+ cytotoxic T cells are activated by the TCR-mediated recognition of their specific antigen
presented on MHC Class I on antigen-presenting cells (first signal) and - by analogy to CD4+
T cells - by costimulatory ligands, e.g. CD80/CD86 (second signal). This second signal can be
modified or even replaced by soluble factors released by activated T helper cells. Once activated,
CD8+ T cells undergo clonal expansion and circulate through the body until they encounter their
specific antigen once again. If an activated CD8+ T cell recognizes its specific antigen on a po-
tential target cell, it either induces apoptosis intrinsically by releasing granules containing perforin
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Table 1.4: Characteristics of helper T cell subtypes
Helper T
cell subtype
Main function Biomolecular
characteristics
Inductive
cytokine
milieu
Th1 Secretion of IFN-, activation of
macrophages and CD8+ T cells,
antibody class switch to IgG
T-bet,
STAT4
IL-2, IL-12
Th2 Secretion of IL-4, IL-5, IL-9,
IL-10 and IL-13, activation of
Eosinophils, Basophils and B cells,
antibody class switch to IgE
GATA3,
STAT6
IL-4
Th3 Secretion of TGF- and IL-10,
promotion of tolerance against
nonpathogenic non-self antigens
in the intestinal mucosa
Unknown TGF-
Th9 Secretion of IL-9, IL-10 and
IL-21, promotion of allergic
inflammation
STAT6,
PU.1, IRF4,
GATA3
IL-4,
TGF-
Th17 Secretion of IL-17A, IL-17F,
IL-21 and IL-22, maintenance of
mucosal barrier function and
pathogen clearance
STAT3,
ROR,
ROR
TGF-,
IL-6, IL-21,
IL-23
Tfh Expression of CD40L, secretion
of IL-4 and IL-21, promotion of
selection and survival of B cells in
germinal centers of lymph follicles
CXCR5,
Bcl-6
IL-21
Treg Secretion of IL-10 and TGF-,
depletion of IL-2 by its high
affinity receptor chain CD25,
suppression of immune responses
by CTLA-4 expression
FoxP3 IL-2,
TGF-
and granzymes or extrinsically by Fas-interaction. Since CD8+ cytotoxic T cells bindMHCClass
I bound antigens, their most common target cells are virus infected somatic cells, transplants and
tumor cells.
B cells comprise the second axis of the adaptive immune system and are capable of recognition
of unprocessed and non-presented antigens by their B cell receptor (BCR), which consists of a
membrane bound immunoglobulin (IgM or IgD) in complex with an Ig/ sheath containing
immunoreceptor tyrosine activation motifs (ITAMs). Antigen engagement induces BCR cross-
linking and ITAM phosphorylation in B cells, which are the initial events of the intracellular
signal transmission cascade leading to the activation of the cell (first signal) and presentation of
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the processed antigen on MHC Class II. The latter allows the recruitment of a cognate CD4+ T
cell, that is specific for the same antigen and contributes to the full activation of the B cells. In-
terestingly, the kinetic segregation model (size-based exclusion of inhibitory phosphatases upon
peptide binding to the TCR or BCR) established for T cell activation seems to be transferrable to
B cell activation considering the strong requirement of the phosphatase activity of CD45 (T cells)
and CD148 (B cells) for TCR- or BCR-mediated activation, respectively (Harwood and Batista,
2010). Both the location of an activated B cell in secondary lymphatic organs and the cytokine
milieu conditioned by surrounding T helper cells modify its activation process and differentiation.
When activated, a B cell either starts producing high amounts of low-affinity immunoglobins
(mainly IgM) or enters the germinal center of a lymph follicle in a secondary lymphatic organ.
Inside the germinal centers B cells undergo a process called somatic hypermutation, that leads to
increased affinity of the variable fragment of the produced antibodies by random mutation of the
germline VDJ rearrangements and subsequent selection of clones that successfully performed this
process (Victora and Nussenzweig, 2012). Thereafter, B cells differentiate either in long living
memory B cells or high-affinity antibody-producing plasma cells. The following table shows key
characteristics of the five different subclasses of immunoglobins (Table 1.5).
Table 1.5: Characteristics of immunoglobin subclasses
Immuno-
globin
Main function Distribution Molecular
structure
IgA Antibody-dependent cellular
cytotoxicity
Serum and
secretions (e.g.
salivary, breast milk)
Dimer fused
by a J chain
IgD B cell receptor Membrane-bound Monomer
IgE Activation of mast cells,
antibody-dependent cellular
cytotoxicity
Serum Monomer
IgG Activation of complement,
antibody-dependent cellular
cytotoxicity, neutralization
Serum Monomer
IgM Activation of complement,
neutralization and B cell
receptor
Serum and
membrane-bound
Pentamer
fused by a J
chain
1.3.2 Regulatory T cells
Regulatory T cells (Treg) comprise about 5-10% of peripheral CD4+ T cells and are molecularly
characterized by the expression of their hallmark-transcription factor Forkhead box P3 (FoxP3).
These cells act suppressive on other lymphocytes and APCs by various mechanisms and naturally
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antagonize overwhelming inflammation and autoimmunity. First evidences for the existence of T
cells with suppressive capacity came from early thymectomy experiments performed by Nishizuka
and Sakaguchi (Nishizuka and Sakakura, 1969; Sakaguchi et al., 1982). They could show that
neonatal thymectomy between 2 and 4 days after birth resulted in severe tissue-inflammation,
which was mediated by auto-reactive T cells. Further studies revealed, that mice having a dysfunc-
tional FoxP3 gene suffered from early onset, T cell-mediated autoimmune diseases like diabetes,
dermatitis and thyreoiditis stressing the relevance of Treg for the maintenance of the immune
homeostasis (Brunkow et al., 2001).
Several mechanisms contribute to the suppressive capacity of Treg: first, Treg constitutively ex-
press the high-affinity IL-2 receptor--chain (CD25), which is usually expressed only upon acti-
vation on other T cell subsets. Therefore, Treg are capable of scavenging soluble IL-2 due to their
higher affinity for this cytokine and subsequently compromise the growth of IL-2-dependent T
cell subsets, e.g. CD8+ memory T cells (Sharma et al., 2007). Second, Treg induce a tolerogenic
micro-milieu by directly producing suppressive cytokines like IL-10, IL-35 and TGF-. These
cytokines seem to be of great importance for the maintenance of immune homeostasis especially
at immunological barriers like the lungs, the skin and the gut, since mice with a Treg-specific
knockout of IL-10 develop severe auto-immune disorders at these sites (Rubtsov et al., 2008).
Third, Treg highly express CTLA-4, a cell surface receptor for CD80/86, which is known as a cell-
intrinsic immune checkpoint, that induces T cell anergy upon receptor-ligand interaction. How-
ever, CTLA-4 seems to act on Treg differently, since mice lacking CTLA-4 specifically on Treg
showed a reduced suppressive capacity of FOXP3+ Treg, whereas the activation and expansion of
these cells was enhanced under inflammatory conditions. Qureshi et al. could reveal that CTLA-4
down-regulates CD80/86 on APC via trans-endocytosis in vivo and in vitro (Qureshi et al., 2011).
Two other cell surface molecules involved in adenosine metabolism, CD39 and CD72, contribute
to the tolerogenic characteristics of Treg by converting extracellular cAMP into adenosine, which
has a suppressive effect on CD4+ effector T cells (Deaglio et al., 2007). Furthermore, several
other cell surface molecules (e.g. LAG3, TIGIT and GITR) were found to be required for op-
timal Treg function by independent research groups (Josefowicz et al., 2012). Finally, Treg are
capable of direct lysis of target cells (e.g. APC or antigen-specific T cells) by induction of apopto-
sis in a granzyme-dependent manner upon CD3 and CD46 stimulation (Grossman et al., 2004;
Cao et al., 2007).
The importance of Treg for maintaining immune tolerance in peripheral tissues is stressed by the
observation that people bearing a mutation in the FOXP3 gene develop a rare but severe syndrome
called immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (short IPEX),
which is linked to type I diabetes, various allergies, thyroiditis and inflammatory bowel disease with
an onset in early childhood (Bennett et al., 2001). Furthermore, the development or progression
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of autoimmune diseases can be influenced not only by mutations in the FOXP3 gene, but also
by other Treg-related alterations. For example, in 2017 an Australian research group was able to
show that a certain HLA subtype (HLA DR1) can favor Treg differentiation over conventional
T cell differentiation. This observation was made in patients with Goodpasture disease, who were
subsequently protected against the development of this fatal autoimmune disease by the dominant
suppressive character of this polymorphism (Ooi et al., 2017). Since defective Treg functioning
is considered to be frequently involved in various autoimmune reactions, Treg based cell therapy
seems to be a promising strategy in order to re-establish the immune homeostasis, that is broadly
discussed in literature (Miyara et al., 2014).
On the other hand, the suppressive capacity of Treg is hijacked by different tumors in order to
prevent immune rejection and to allow immune escape. The negative prognostic effect of high
intratumoral Treg burden was shown for ovarial (Curiel et al., 2004), gastric (Perrone et al., 2008;
Wu et al., 2018) and hepatocellular (Gao et al., 2007) among others.
1.4 Chemokines
1.4.1 Chemokine families
Chemokines represent a group of chemo-attractant cytokines, which feature chemotactic migra-
tion of immune cells, fibroblasts, endothelial cells, osteoclasts and many others, and are thereby
involved in multiple physiological and pathological processes such as immune response, T cell
selection, wound healing, tissue remodeling, neoangiogenesis and even metastasis (Rossi and Zlot-
nik, 2000). Chemokines are most commonly sub-divided according to their molecular structure,
that depends on the frequency and the orientation of disulfide bonds within their tertiary structure
(Table 1.6).
The so-called CC chemokine ligands (CCLs), which represent the largest sub-group among all
chemokines having 27 distinct members (CCL1-CCL28, CCL9 and CCL10 are considered to
be the same molecule), have two directly adjacent cysteins (C) forming disulfide bonds near the
amino terminus of the protein. There are CC chemokines with four or six cysteine residues, respec-
tively. These chemokine ligands interact with their corresponding chemokine receptors (CCRs)
and induce migration in many different cells, e.g. CCL1 and CCL2 in monocytes and dendritic
cells, CCL5 in T cells, CCL9 in osteoclasts and CCL17 and CCL22 in regulatory T cells.
The second largest group of chemotactic cytokines are the CXC chemokines (CXCLs) compris-
ing 17 known members. In this family, the two N-terminal cysteine residues or disulfide bonds,
respectively, are separated by one other amino acid. The CXC chemokines are widely involved in
the attraction of monocytes, dendritic cells and T cells but are also found to have either pro- or
12
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anti-angiogenic properties depending on the presence or absence of the amino acid motif ELR
being located right before the first cysteine of the CXC sequence (Vandercappellen et al., 2008).
Their corresponding receptors are called CXC receptors (CXCRs).
TheC chemokines (XCLs) represent another group of chemokines containing only two cysteines in
their molecular structure leading to the formation of one disulfide bond. This group has two mem-
bers, which are called XCL1 (lymphotactin-) and XCL2 (lymphotactin-). Both chemokines
are capable of attracting T cells via the interaction with their mutual receptor XCR1.
CX3CL1 forms the last and smallest chemokine family having only one member. In this pro-
tein the two disulfide bonds are separated by three other amino acids. Interestingly, CX3CL1
combines the features of chemokines and adhesion molecules since it is not only secreted into the
extracellular space but also tethered to the membrane of the cell (Bazan et al., 1997).
Table 1.6: Chemokine families
Family Members Molecular Structure
CCL 27
NC
C
C
C
CXCL 17
NC
C
CX
C
XCL 2
NC
C
CX3CL 1
NC
C
C
C
XXX
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1.4.2 The chemokine CCL22
CCL22 is a chemokine of the CC chemokine family. It has been first described as a macrophage
derived chemokine (MDC) by Godiska et al. in 1997 and was found to have chemoattractive prop-
erties on macrophages, monocyte-derived dendritic cells and natural killer cells (Godiska et al.,
1997). Only one year later, researchers from the same group identified the chemokine receptor
CCR4 as the functional receptor of CCL22 (Imai et al., 1998). Since then, many new aspects
concerning the role of this particular chemokine on immune response and homeostasis have been
revealed.
The first hint that CCL22 might not only have effects on the innate immune system and its cells
but also play a role in orchestrating adaptive immune responses came from a Japanese group: they
showed that dendritic cells and CD4+ T cells form clusters in human skin and secondary im-
mune tissues in a CCL22-CCR4-dependent way (Katou et al., 2001). Although the distinct T
cell subsets, which were found to interact with dendritic cells in this study, haven’t been further
characterized by the researchers, results from other groups suggest that regulatory T cells (Iellem
et al., 2001) and Th2 cells (Bonecchi et al., 1998) express CCR4 predominantly. Although CCR4
might not be the only receptor for CCL22 (Struyf et al., 1998), the association of CCL22 and
regulatory T cells was highlighted by several following studies in various ways (Eby et al., 2015;
Yang et al., 2012; Ménétrier-Caux et al., 2012).
In recent years, even therapeutic strategies hijacking the CCL22-CCR4 axis have been proposed.
In 2011, Montane et al. published a novel and successful strategy to delay or even prevent the on-
set of murine autoimmune diabetes by CCL22-mediated recruitment of Treg into pancreatic islets
(Montane et al., 2011). In this study the authors injected CCL22-encoding adenoviruses into the
pancreatic duct of non-obesity diabetes (NOD) mice and achieved long-lasting insulin produc-
tion of the pancreatic islets due to Treg infiltration and subsequent protection from autoimmune-
mediated destruction.
Additionally, CCL22 has been considered as a potential target for therapeutic approaches in tumor
therapy. Over the past years, several studies revealed a role of CCL22 in establishing and maintain-
ing an immune-suppressive micromilieu within tumors by attracting regulatory T cells. Therefore,
Rapp et al. tried to exploit this finding by stably transducing tumor-specific CD8+ T cells with
CCR4, shifting the CCL22-mediated preferential recruitment of Tregs towards anti-tumor di-
rected cytotoxic T cells (Rapp et al., 2016). Through this approach, the number of tumor-specific
T cells could be strongly enriched and tumor growth was repressed significantly in a murine subcu-
tanous pancreatic carcinomamodel. Most recently, an American group could restrict the growth of
melanomas and lungmetastases ofmelanomas by repetitive gen gun injections of CCL22-encoding
plasmids into the skin of mice by trapping Treg at the injection site and preventing tumor homing
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of these cells (Klarquist et al., 2016). Furthermore, the authors could show that not only tumor
growth was reduced in treated mice, but also autoimmune disorders affecting the skin (e.g. vi-
tiligo), which are common side effects of checkpoint-inhibitors, were remarkably attenuated by
this strategy.
Thus, CCL22 remains to be a promising candidate for future therapeutic approaches for both
autoimmune and malignant diseases and needs to be further evaluated in clinical studies in order
to translate the recent findings from bench to bedside.
1.5 Chemokine receptors
There are two types of chemokine receptors, namely typical and atypical chemokine receptors.
Whereas typical chemokine receptors are seven-transmembrane G-protein coupled receptors, that
induce migration and activation after intracellular calcium release, atypical chemokine receptors,
that seem to be structurally homologous to their counterpart, lack conventional downstream intra-
cellular signaling. For many years, the existence and the function of these atypical receptors have
been unknown.
In recent years, research on atypical chemokine receptors such as CCRL1 suggested that these
receptors could hold evidence for an almost forgotten hypothesis, namely the source and sink hy-
pothesis (Ulvmar et al., 2014). According to this hypothesis, which was introduced by Francis
Crick in the field of embryology for the first time in 1970, the development of functional gradi-
ents based on diffusion requires both a source producing the diffusing molecule and a sink locally
removing the molecules out of the system and thereby shaping the gradient (Crick, 1970). Fol-
lowing this hypothesis, the atypical chemokine receptors act as scavenger receptors allowing the
development of functional chemokine gradients, which are in turn recognized by typical chemokine
receptors and can then be translated into migration of cells.
In analogy to the classification of chemokines, there are four families of typical chemokine re-
ceptors. The first group, the so-called CC chemokine receptors (CCRs), comprise a family of 11
members, which all bind CCL chemokines. This family covers some of the most famous mem-
bers of all chemokine receptors including CCR5, CCR7 and CCR11, which have been intensively
investigated over the last couple of years. CCR5, for instance, was shown to be a co-receptor for
HIV-1, the virus causing acquired immunodeficiency syndrome (AIDS), and was subsequently
identified as a promising therapeutic target for HIV treatment (Deng et al., 1996; Fätkenheuer
et al., 2005). Moreover, CCR7 was found to mediate CCL19- and CCL21-dependent lympho-
cyte trafficking and homing to secondary lymphoid organs such as lymph nodes and to be a hall-
mark of residual memory T cells (Baekkevold et al., 2001; Sallusto et al., 1999). The ability of
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CCR11 to bind CCL19, CCL21 and CCL25 was responsible for its allocation to the CCR fam-
ily, although subsequent research could show that CCR11 acts as atypical chemokine receptor.
Therefore, CCR11 was renamed as CCRL1 and remained as a historical remnant in this family.
Another member of the CC chemokine receptor family is CCR4. CCR4 is capable of recogniz-
ing CCL2, CCL4, CCL5, CCL17 and CCL22 but seems to have different affinities and to react
differently depending on its ligands (Mariani et al., 2004). Apart from its predominant expression
on Treg, CCR4 was described to have major effects in regulating innate immune responses upon
LPS-induced endotoxic shock (Chvatchko et al., 2000).
The CXC chemokine receptors (CXCRs) represent the second largest family of chemokine re-
ceptors. The seven members of this family (CXCR1-CXCR7) are bound by CXC chemokines
and are equally relevant in terms of immune homeostasis and response as the CC chemokine re-
ceptors. Among these chemokine receptors CXCR4 is the most famous one due to its high clinical
relevance. Notably, CXCR4 was found to be another important co-receptor for HIV-1 in addition
to CCR5 (Feng et al., 1996) and seems to regulate hematopoietic stem cell homing to the bone
marrow and stem cell quiescence (Möhle et al., 1998). Exploiting this property, a drug blocking
CXCR4 is now officially approved to efficiently mobilize stem cells for stem cell transplantation in
combination with G-CSF after the substantial enhancement of stem cell mobilization by CXCR4
blockage was described earlier in the literature (Dar et al., 2011).
The two remaining families of chemokine receptors contain only one particular member. XCR1,
the only member of the C chemokine receptor family, is known to recognize both XCL1 and
XCL2, and was found to be a hallmark of a specific subset of dendritic cells. These XCR1+
CD11c+ CD141+ dendritic cells are highly specialized in cross-presenting antigens to CD8+ T
cells and seem to resemble murine CD11c+ CD8+ dendritic cells in humans (Dorner et al., 2009;
Bachem et al., 2010).
In turn, CX3CR1 comprises the last chemokine receptor family (CX3C chemokine receptor fam-
ily) and is predominantly expressed by lymphocytes and monocytes. In the central nervous system
CX3CR1+ monocytes were identified to modulate learning abilities in the context of systemic in-
flammation by releasing TNF- and inducing subsequent dendritic spine remodeling (Garré et al.,
2017).
Since the existence of atypical chemokine receptors is a very recent discovery, there is no such
classification as for the typical chemokine receptors. However, the inconsistent nomenclature for
these receptors were partially reversed when four of them were renamed in ACKR1-4 by the Hu-
manGenomeOrganizationGeneNomenclature Committee andNomenclature Committee of the
International Union of Pharmacology in 2013 (Table 1.7, adopted and modified from Bachelerie
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et al. (Bachelerie et al., 2014)). The confirmation of two more receptors (CCRL2 and PITPNM3)
as atypical chemokine receptors is still pending.
Table 1.7: Atypical chemokine receptors
Name Synonyms Ligands Expression
Pattern
Function
ACKR1 DARC,
Duffy
antigen,
CD234
CCL2, CCL7,
CCL8, CCL13,
CCL14, CCL16,
CCL17, CCL22,
CXCL1, CXCL5,
CXCL6, CXCL7,
CXCL8, CXCL9,
CXCL11, CXCL13
Erythrocytes,
neurons, vascular
endothelial cells
Ligand
transcytosis
and
presentation,
ligand sink
and reservoir
ACKR2 D6,
CCR9,
CCR10
CCL2, CCL3,
CCL3L1, CCL4,
CCL5, CCL7,
CCL8, CCL11,
CCL13, CCL14,
CCL17, CCL22
Lymphatic
endothelial cells,
syncytiotro-
phoblast
Ligand
scavenging
ACKR3 CXCR7,
RDC1
CXCL11, CXCL12 Hematopoietic
cells, neurons,
mesenchymal
cells, endothelial
cells, cancer cells
Ligand
scavenging,
gradient
shaping
ACKR4 CCRL1,
CCR11
CCL19, CCL21,
CCL25, CXCL13
Lymphatic
endothelial cells,
thymic epithelial
cells, bronchial
epithelial cells,
keratinocytes
Ligand
scavenging,
gradient
shaping
As mentioned above, the common feature of atypical chemokine receptors is the scavenging of
chemokines. Nevertheless, the distinct receptors differ in the exact mechanism of scavenging and
some of them seem to influence chemotaxis in other, more elaborate ways (Nibbs and Graham,
2013). For instance, ACKR1 is able to transport chemokines from the blood through endothelial
cells and thereby facilitates transcytosis of chemokines into the subendothelial tissue (Pruenster
et al., 2009). Furthermore, atypical chemokine receptors were also found to influence the down-
stream signaling of the conventional chemokine receptor CXCR4 by heterodimerization (Levoye
et al., 2009).
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However, the understanding of the function of atypical chemokine receptors, their involvement
in immune regulation and their expression profile is still very poor and further experimental work
is required to elucidate the biological role of this interesting receptor family.
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Definition of the project
The chemokine CCL22 seems to play a pivotal role for intratumoral recruitment of regulatory T
cells and subsequent immune escape in many solid tumor entities. However, immunohistochem-
ical staining revealed that only in a few tumor entities the tumor cells themselves are capable to
produce CCL22. In contrast, immune cells infiltrating the tumor frequently show a strong stain-
ing for CCL22. Thus, CCL22 production seems to be a tightly regulated process that is highly
dependent on tumor-immune cell crosstalk.
However, the regulatory mechanisms leading to CCL22 expression in bystander immune cells
have not been investigated so far and may offer a promising therapeutic target for cancer treatment
strategies in the future.
This thesis aims at understanding of the regulatory mechanisms that influence the expression of
the Treg-attracting chemokine CCL22 in the tumor micromilieu. In particular, our research group
was interested in (1) the cell type that is responsible for the intratumoral production of CCL22,
(2) the factors that are produced by tumor cells inducing the expression of CCL22 in immune cells
and (3) the evaluation of potential pharmacologic targets in this cascade.
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Results
The publications covered by this thesis elucidate two important regulatory mechanisms concerning
the expression of CCL22, a Treg-attracting chemokine. The first paper shows that many tumor
cell lines are capable of inducing CCL22 expression and that IL-1 produced by human pancre-
atic adenocarcinoma cells is an important positive regulator of CCL22 production. IL-1 is a
mainly membrane-bound but also secreted cytokine with many known immunoregulatory effects.
Its role on tumor growth and disease progression has been investigated extensively. The findings
published in this paper add another role of tumor-derived IL-1 that can directly be linked to
Treg migration and Treg-mediated immunosuppression. Notably, anakinra, a recombinant IL-1
receptor antagonist was able to fully inhibit the CCL22-induced Treg migration in vitro and may
represent a promising therapeutic strategy to reduce Treg-infiltration in solid tumors.
The second paper focuses on novel mechanisms and pathways, that directly suppress CCL22 pro-
duction within tumors and might also be used therapeutically in the future. In detail, treatment
of tumor-bearing mice with Toll-like receptor agonists such as the oligodesoxynucleotide CpG
and the small molecule R848 as well as with the RIG-I-like helicase agonists poly(I:C) was found
to reduce the intratumoral number of Treg and to slow down tumor growth significantly. Inter-
estingly, CpG indirectly suppressed the migration of Treg into the tumor by reducing the expres-
sion of the Treg-attracting chemokines CCL17 and CCL22. In contrast, other pro-inflammatory
chemokines such as CCL5 were induced upon TLR9 treatment. Confocal microscopy revealed
that intratumoral macrophages and dendritic cells are the CCL22 producing source within hu-
man tumors and respond with downregulation of CCL22 expression when CpG is administered.
This effect was mediated by type-I interferons (especially IFN-), which is released due to TLR
stimulation by immune cells. Furthermore, when CCL22 production was maintained in CCL22
over-expressing cell lines, CpG treatment failed to repress tumor growth in vivo due to maintained
Treg infiltration.
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Summary
Regulatory T cells and their contribution to tumorigenesis and tumor growth are of high interest
both for basic and translational medical research. By now, it is well accepted that regulatory T cells
play an essential role in establishing and maintaining the intratumoral immunosuppression. They
may therefore represent a favorable target for immune-modulating cancer therapies. At the same
time, Treg physiologically control overwhelming immune responses and autoimmunity by directly
inhibiting self-directed T and B cells. Thus, treatment strategies that alter their function or even
deplete the respective cell population using Treg-specific antibodies bear the danger of inducing se-
vere autoimmune side effects. In order to circumvent these limitations, novel Treg-based strategies
are urgently needed to overcome the Treg-induced intratumoral immunosuppression. Inhibiting
the infiltration of tumors by Treg without altering the numbers or the function of Treg in other
parts of the organism may represent a promising approach to selectively change the immunological
milieu within a tumor without putting the patient’s health at risk.
Taken together, both papers stress the relevance of the chemokine CCL22 for Treg migration
into tumor tissue and reveal two novel strategies for the blockage of the CCL22-Treg axis in order
to overcome Treg-mediated immunosuppression within solid tumors (see Fig. 4.1 for a graphic
summary).
Regulatorische T Zellen und ihr Beitrag zu Tumorigenese und Tumorwachstum sind sowohl
für die Grundlagenforschung als auch die translationale medizinische Forschung von großem In-
teresse. Mittlerweile gilt es als weithin akzeptiert, dass regulatorische T Zellen eine essentielle
Rolle für die Etablierung und Aufrechterhaltung einer intratumoralen Immunsuppression spie-
len. Deshalb könnten sie ein vielversprechendes Ziel von immunmodulierenden Therapieoptio-
nen bei Krebs darstellen. Gleichzeitig aber kontrollieren Treg in ihrer physiologischen Funktion
überschießende Immunantworten und Autoimmunität durch direkte Inhibition von aktivierten
oder autoimmun wirksamen T und B Zellen. Daher bergen Therapiestrategien, die die Funk-
tion oder die Anzahl von Treg z.B. mittels Treg-spezifischen Antikörpern verändern, die Gefahr,
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schwerwiegende autoimmun-vermittelte Nebenwirkungen zu induzieren. Um diese therapeutis-
chen Limitationen zu umgehen und gleichzeitig die intratumorale, Treg-vermittelte Immunsup-
pression zu durchbrechen, werden neuartige Treg-basierte Therapieoptionen dringend benötigt.
Somit könnte eine Therapie-induzierte, verminderte Infiltration des Tumors durch Treg ohne
Veränderung der Funktion undAnzahl der regulatorischenTZellen im sonstigenOrganismus eine
vielversprechendeMaßnahme sein, selektiv das intratumorale Milieu zu verändern, ohne dabei die
Gesundheit des Patienten zu gefährden.
Zusammengefasst betonen beide Originalarbeiten die Relevanz des Chemokins CCL22 für die
Migration von regulatorischenTZellen in Tumore und zeigen zwei neuartige Strategien zur Block-
ade der CCL22-Treg-Achse und der durch sie vermittelten intratumoralen Immunsuppression auf
(siehe auch Fig. 4.1 für eine graphische Zusammenfassung).
CD4+
Teff
DC
Treg
Reduced Anti-Tumoral Eect of Tes
Tumor
IL-2
IL-1α
CCL22
CpG
Anakinra
IL-10
TGF-beta
Figure 4.1: Regulation of CCL22 production in solid tumors
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Publications
5.1 Cancer cell-derived IL-1 induces CCL22 and the recruitment of
regulatory T cells
5.1.1 Own contribution to the original article
Thepaper ”Cancer cell-derived IL-1 inducesCCL22 and the recruitment of regulatory T cells” fo-
cuses on the mechanism responsible for the up-regulation and the cellular source of the chemokine
CCL22 in solid tumors. My experiments revealed that dendritic cells isolated from human blood
respond to the co-incubation with tumor cell supernatants with the up-regulation of CCL22,
whereas the DC-depleted cell fraction or CD14+ monocytes didn’t show this phenotype (Figure
3C and unpublished data). Using qRT-PCR analysis I could show that IL-1 and IL-1 are het-
erogeneously expressed in human andmurine cancer cell lines, which were tested to induce CCL22
in vitro (Figure 4B and Supplemental figure 2C). I validated this finding in two cell lines at pro-
tein level using ELISA (Figure 4A). In order to prove that IL-1 was responsible for the inductive
effect of the tumor-conditioned media in our system, I blocked IL-1 signaling by the addition of
a recombinant IL-1 receptor antagonist called anakinra (Figure 4C) and tested if recombinant IL-
1 was able to induce CCL22 in PBMC cultured in standard medium (Supplemental Figure 2D).
Furthermore, I could demonstrate that transcriptional regulation was the underlying mechanism
for the increased CCL22 production using a luciferase reporter assay in HEK cells (Supplemental
Figure 4E). Moreover, I evaluated the functional relevance of the expression of IL-1 by tumor cells
using a transwell migration assay and found increased migration of regulatory T cells towards the
supernatants of PBMC that were co-incubated with tumor-conditioned medium (Figure 5). My
contribution to this paper was rewarded with a shared first authorship. All supplemental figures
can be accessed via the official homepage of Oncoimmunology.
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5.1.2 Original article
The original article ”Cancer cell-derived IL-1 induces CCL22 and the recruitment of regulatory
T cells” can be accessed at https://www.tandfonline.com/doi/full/10.1080/2162402X.2016.1175794
and is cited as follows:
Wiedemann G.M., Knott M.M.L., Vetter V.K., Rapp M., Haubner S., Fesseler J., Kühnemuth
B., Layritz P., Thaler R., Kruger S., et al. Cancer cell-derived IL-1 induces CCL22 and the
recruitment of regulatory T cells. Oncoimmunology. 2016;5:e1175794.
doi: 10.1080/2162402X.2016.1175794.
5.2 Suppression of intratumoral CCL22 by type I interferon inhibits
migration of regulatory T cells and blocks cancer progression
5.2.1 Own contribution to the original article
The second publication ”Suppression of Intratumoral CCL22 by Type I Interferon Inhibits Mi-
gration of Regulatory T Cells and Blocks Cancer Progression” addresses the mechanism of TLR
agonist-mediated tumor growth inhibition. The results published in this article convincingly show
that treatment of subcutaneous tumors with the TLR9 agonist CpG leads to significant reduction
of tumor size and complete response in some animals. This effect was highly dependent on the
suppression of CCL17- and CCL22-mediated Treg infiltration by Type I interferons secreted in
response to CpG treatment. Constitutive expression of CCL22 by the tumor cells was able to fully
revert this effect.
I substantially contributed to the review process of this paper by performing a time-course CT26
tumor model with or without CpG treatment and compared the tumor growth, the infiltration by
Treg and other immune cells after 4 and 8 days. My experiments revealed that CpG treatment had
a long lasting effect on the immunological micromilieu in subcutaneous solid tumors (Supplemen-
tal Figure 1C). Furthermore, I evaluated the effect of IFN- (the putative downstream mediator
of CpG) treatment of tumor-bearing mice in two different tumor models. I could observe a trend
towards reduced levels of CCL22 on protein level in IFN- treated mice and a reduced infiltra-
tion by Treg in CT26 and Panc02 tumors. Both findings were not significant though, suggesting
a superior effect of CpG versus IFN- administration (Supplemental Figure 6B). Interestingly,
my experiments also showed that successful CpG treatment induced memory (Supplemental Fig-
ure 7A) in CT26 tumor bearing mice. Moreover, CD8+ T cells showed an increased specificity
towards the tumor specific antigen AH1 (Supplemental Figure 7B) after CpG treatment, most
likely due to the reduced number of intratumoral Treg. My contribution to this paper was re-
warded with a co-authorship. All supplemental figures can be accessed via the official homepage
of Cancer Research.
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5.2. Suppression of intratumoral CCL22 by type I interferon inhibits migration of regulatory T cells and
blocks cancer progression
5.2.2 Original article
The original article ”Suppression of intratumoral CCL22 by type I interferon inhibits migration of
regulatory T cells and blocks cancer progression” can be accessed at https://cancerres.aacrjournals.
org/content/75/21/4483.long and is cited as follows:
Anz D, RappM, Eiber S, Koelzer VH,Thaler R, Haubner S, Knott M, Nagel S, Golic M,Wiede-
mann GM, Bauernfeind F, Wurzenberger C, Hornung V, Scholz C, Mayr D, Rothenfusser S,
Endres S, Bourquin C. 2015. Suppression of intratumoral CCL22 by type I interferon inhibits
migration of regulatory T cells and blocks cancer progression. Cancer Res 75(21):4483–4493.
doi: 10.1080/2162402X.2016.1175794.
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